PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 14616695

Vancomycin-resistant Staphylococcus aureus: no apocalypse now.

F W Goldstein·M D Kitzis
View original source ↗Export metadata ↓

Abstract

The number of reports concerning vancomycin-resistant Staphylococcus aureus is much higher than the number of true resistant strains or unexpected clinical failures. Many confounding factors, including inadequate serum levels, severely ill patients, foreign devices or undrained abscesses, are more likely to be responsible for the clinical failures than resistance to vancomycin.

Explore related subjects

Drug Therapy, CombinationHumansStaphylococcus aureusTeicoplaninVancomycinVancomycin ResistanceEditorial

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

F W Goldstein, M D Kitzis. 2003. Vancomycin-resistant Staphylococcus aureus: no apocalypse now.. https://doi.org/10.1046/j.1469-0691.2003.00734.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

[Revision of the recommendations of the Commission on Pharmacotherapy of the German Society for Rheumatology. Comment on the use of mycophenolic acid for systemic lupus erythematosus].

According to the NIH scheme, the "evidence based medicine" standard in the treatment of severe proliferative lupus-nephritis is cyclophosphamide in combination with steroids. Undesired effects, therapy resistance, and deficient long-term effects underscore the necessity for the development of alternative therapies for the treatment of organ involvement. Mycophenolate mofetil (MMF) possesses the potential to decisively improve the therapeutic possibilities for systemic lupus erythematosus (SLE). On the basis of the available data, MMF represents an alternative to the current standard therapies for severe lupus-nephritises and shows less toxicity. MMF is also effective in patients with other manifestations refractory to conventional therapy. Questions remain unanswered on the optimal dosage and possible reduction in cases of remission. In addition, the duration of maintenance therapy is unclear. Therefore, large, prospective, randomized clinical studies in the treatment of lupus-nephritis with a sufficiently long follow-up phase are underway.

Drug Therapy, Combination↗